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Abstract
 
Human natural killer (NK) cells express a series of activating receptors and coreceptors that are
involved in recognition and killing of target cells. In this study, in an attempt to identify the
cellular ligands for such triggering surface molecules, mice were immunized with NK-suscepti-
ble target cells. On the basis of a functional screening, four mAbs were selected that induced a
partial down-regulation of the NK-mediated cytotoxicity against the immunizing target cells.
As revealed by biochemical analysis, three of such mAbs recognized molecules of 
 
 
 
70 kD. The
other mAb reacted with two distinct molecules of 
 
 
 
65 and 60 kD, respectively. Protein puri-
fication followed by tryptic digestion and mass spectra analysis, allowed the identification of the
70 kD and the 65/60 kD molecules as PVR (CD155) and Nectin-2 
 
 
 
/
 
 
 
 (CD112), respec-
tively. PVR-Fc and Nectin-2-Fc soluble hybrid molecules brightly stained COS-7 cells
transfected with the DNAM-1 (CD226) construct, thus providing direct evidence that both
PVR and Nectin-2 represent specific ligands for the DNAM-1 triggering receptor. Finally, the
surface expression of PVR or Nectin-2 in cell transfectants resulted in DNAM-1–dependent
enhancement of NK-mediated lysis of these target cells. This lysis was inhibited or even virtu-
ally abrogated upon mAb-mediated masking of DNAM-1 (on NK cells) or PVR or Nectin-2
ligands (on cell transfectants).
Key words: natural killer cells • tumors • activating receptors • cellular ligands • protein sequencing
 
Introduction
 
In humans the function of NK cells is regulated by a series
of surface receptors that either inhibit or enhance the NK-
mediated cytolytic activity. When NK cells encounter
potential target cells, clonally distributed killer inhibitory
Ig-like receptors (KIR) and/or the CD94/NKG2A het-
erodimer sense the expression of HLA class I molecules at
the cell surface (1–4). When appropriate inhibitory recep-
tor/HLA class I ligand interactions occur, the receptors
deliver negative signals that inhibit the NK-mediated kill-
ing. On the other hand, in the absence of such interactions,
as it may occur in tumor or virus infected target cells, (non-
HLA class I–specific) activating receptors are allowed to
deliver triggering signals to NK cells resulting in target cell
killing. Several non-HLA class I–specific activating recep-
tors have been identified including NKp46, NKp30, and
NKp44 (collectively termed “natural cytotoxicity recep-
tors”, NCR) and NKG2D (5, 6). While the expression of
NCR is restricted to NK cells, NKG2D is also expressed
by virtually all TCR 
 
 
 
/
 
 
 
 
 
 as well as by CD8
 
 
 
 TCR 
 
 
 
/
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T cells. The combined mAb-mediated masking of both
NCR and NKG2D results in strong inhibition of the NK
cytotoxicity against most target cells. This suggests that
NCR and NKG2D play a predominant role in target cell
recognition and killing by NK cells. However, additional
surface molecules have been implicated in this process.
These include 2B4 (CD244), NTB-A, and NKp80 that ap-
pear to function as coreceptors since their triggering func-
tion is dependent on the simultaneous engagement of
NCR (7–9). Another surface molecule that has been
shown to participate in the induction phase of NK cell acti-
vation is the leukocyte adhesion molecule DNAX acces-
sory molecule-1 (DNAM-1; CD226; references 10 and
11). DNAM-1 is expressed by virtually all NK cells, T
cells, and monocytes. Encoded on human chromosome 18,
DNAM-1 is characterized by two Ig-like domains in the
extracellular portion and a cytoplasmic tail containing three
tyrosine residues. Cross-linking of DNAM-1 results in
Fyn-mediated tyrosine phosphorylation and triggering of
cytotoxicity in NK cells (11). Remarkably, DNAM-1
function is dependent on the surface expression of lym-
phocytes function-associated antigen 1 (LFA-1; CD18/
CD11a). Indeed, it is defective in NK cells from patients
with leukocyte adhesion deficiency syndrome 1 (LAD1),
who lack LFA-1 but express DNAM-1. In this case the
function could be rescued upon genetic reconstitution of
LFA-1 (12).
Although functional data would indicate that the vari-
ous activating NK receptors and coreceptors recognize
ligands expressed at the target cell surface, so far only few
of these ligands have been identified. For example
NKG2D recognizes the stress-inducible MHC class I–related
chain molecules (MIC)A/B and UL16-binding protein
(ULBP) molecules (13–15) while 2B4 specifically interacts
with CD48 (16, 17). On the other hand, NCR, NTB-A,
NKp80, and DNAM-1 are orphan receptors since their
cellular ligands are still unknown. In an attempt to identify
such ligands, we generated mAbs by immunizing mice
with NK-susceptible target cells. These mAbs were
screened for their ability to interfere with the NK-medi-
ated cytotoxicity against the immunizing target cells. Us-
ing this functional approach we were able to identify two
molecules, poliovirus receptor (PVR) (18) and Nectin-2
(19, 20), that specifically induce NK cell activation by in-
teracting with DNAM-1.
 
Materials and Methods
 
Monoclonal Antibodies.
 
M5A10 and M2C24 or L95 and L14
mAbs were obtained by immunizing a 5-week-old BALB/c
mouse with M14 (human melanoma) or 293T (embryonic fibro-
blast) cell lines respectively as described previously (8). The fol-
lowing mAbs, selected in our lab, were used in this study: GN18,
KRA236, and FS123 (IgG3, IgG1, and IgG2a, respectively, anti-
DNAM-1), BAB281 and KL247 (IgG1 and IgM, respectively,
anti-NKp46), Z231 and KS38 (IgG1 and IgM, respectively, anti-
NKp44), Z25 and F252 (IgG1 and IgM, respectively, anti-
NKp30), PP35 (IgG1, anti-2B4), BAT221 (IgG1, anti-NKG2D),
c127 (IgG1, anti-CD16), c218 (IgG1, anti-CD56), MA152
(IgG1, anti-NKp80), MA127 (IgG1, anti-NTB-A), BAM195
(IgG1, anti-MICA), and JT3A (IgG2a, anti-CD3).
D1.12 (IgG2a, anti-HLA-DR) mAb was provided by Dr. R.S.
Accolla (University of Insubria, Varese, Italy). HP2.6 (IgG2a,
anti-CD4) mAb was provided by Dr. P. Sanchez-Madrid (Uni-
versidad Autonoma de Madrid, Madrid, Spain). M295 (IgG1,
anti-ULBP1), M310 (IgG1, anti-ULBP2), and M551 (IgG1,
anti-ULBP3) were provided by Immunex, Seattle, WA. TU145
(IgM, anti-CD48) was purchased from Becton Dickinson.
 
Polyclonal NK and T Cell Populations and NK Cell Lines.
 
PBMCs,
derived from healthy donors, were isolated on Ficoll-Hypaque
gradients and PBLs were obtained by depleting PBMCs of plas-
tic-adherent cells. Enriched NK cells were isolated by incubating
PBLs with anti-CD3 (JT3A), anti-CD4 (HP2.6), and anti-HLA-
DR (D1.12) mAbs (30 min at 4
 
 
 
C) followed by goat anti–mouse
coated Dynabeads (Dynal; 30 min at 4
 
 
 
C) and immunomagnetic
depletion (8). CD3
 
 
 
 4
 
 
 
 DR
 
 
 
 cells were cultured on irradiated
feeder cells in the presence of 100 U/ml rIL-2 (Proleukin; Chi-
ron Corp.) and 1.5 ng/ml PHA (GIBCO BRL) in order to ob-
tain polyclonal NK cell populations. NK92 and YT NK cell lines
were provided by E.O. Long (NIAID, NIH, Rockville, MD)
and E.D. Carosella (Institut Universitaire d’Hematologie, Paris,
France), respectively.
PHA blasts were obtained by culturing for one day PBL with
1.5 ng/ml PHA (GIBCO BRL). After this period of time cells
were washed and cultured in medium supplemented with 100
U/ml of rIL2.
 
Cytolytic Activity and Flow Cytofluorimetric Analysis.
 
NK cells
were tested for cytolytic activity against the indicated target cells
in a 4-h 
 
51
 
Cr-release assay as previously described (8, 15). The
concentrations of the various mAbs added for masking experi-
ments were 10 
 
 
 
g/ml. The E/T ratios are indicated in the text.
In some cytolytic assays, as indicated in the text, to avoid the
involvement of NKG2D-dependent lysis, effector cells were first
incubated with BAT 221 (anti-NKG2D) mAb (10 
 
 
 
g/ml) for 15
min at room temperature (15).
For one-color cytofluorimetric analysis (FACSCalibur™; Bec-
ton Dickinson) cells were stained with the appropriate mAbs fol-
lowed by PE- or FITC-conjugated isotype-specific goat anti–
mouse second reagent (Southern Biotechnology Associates, Inc.;
reference 9). PVR-Fc and Nectin-2-Fc molecules were used at
the concentration of 20 
 
 
 
g/ml followed by PE-conjugated iso-
type-specific goat anti–human second reagent (Southern Bio-
technology Associates, Inc.)
 
Biochemical Characterization of PVR and Nectin-2 Molecules.
 
20 
 
 
 
10
 
6
 
 cells were incubated (15’ at 20
 
 
 
C) in 1 ml PBS pH 8.0 con-
taining 250 
 
 
 
g of EZ-LINK SULFO-NHS-LC-LC-BIOTIN
(Pierce Chemical Co.) and washed three times in Washing Buffer
(10 mM TRIS, pH 8, 0.14 M NaCl). Cells were then lysed in 1%
NP-40 and immunoprecipitated with Sepharose-PA- (Amersham
Biosciences) coupled mAbs. Samples were analyzed by discontin-
uous SDS-PAGE either undigested or digested with N-glycosi-
dase F (Boehringer) and transferred to Immobilon P (Millipore).
After staining with Neutravidin (Pierce Chemical Co.) the Re-
naissance Chemiluminescence Kit (NEN Life Science Products)
was used for detection (8). For Western blotting experiments
mAbs, purified using AKTA PRIME (Amersham Biosciences),
were labeled with Biotin (Pierce Chemical Co.). Neutravidin
(Pierce Chemical Co.) was used as second reagent.
 
PVR and Nectin-2 Purification.
 
To obtain 293T cell mem-
branes, cells were washed twice in PBS pH 7.5 and resuspended
at 10
 
8
 
 cells/ml in ice-cold hypotonic swelling buffer (10 mMT
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Tris-HCl, pH 7.6, 0.5 mM MgCl2, 10 mM 1AA, with protease
inhibitors) for 10’ at 4
 
 
 
C before their disruption with Polytron
3100 (Kinematica AG). Tonicity was restored by adding 10 mM
Tris-HCl, pH 7.6, 0.5 mM MgCl
 
2
 
, 1.5 M NaCl with protease
inhibitors and suspension was centrifuged 5
 
 
 
 at 500 
 
g
 
 at 4
 
 
 
C to re-
move the nuclear fraction. Supernatant, upon addition of EDTA
(at final concentration of 5 mM), was centrifuged 45’ at 150,000 
 
g
 
at 4
 
 
 
C. Pellet was resuspended in 1 ml 1% NP-40 lysis buffer with
protease inhibitors and stored at –80
 
 
 
C. Membrane lysates from
5 
 
 
 
 10
 
9
 
 cells were precleared twice with Sepharose-PA and incu-
bated with Sepharose CnBr-coupled mAbs O/N at 4
 
 
 
 under ro-
tation. After extensive washes, specific proteins were eluted with
0.1 M glycine, 150 mM NaCl, pH 2.8, highly concentrated with
Amicon Ultra (Millipore) and analyzed by discontinuous SDS-
PAGE under nonreducing conditions. To detect the purified
protein polyacrylamide gel was stained using Simply Blue Safe-
stain (Invitrogen) 1 h at room temperature.
 
In-gel Enzymatic Digestion.
 
After the staining procedure, the
gel was washed three times with water for 60 min. The band of
interest was excised using a sterile blade, placed in a 1.5 ml mi-
crotube and cut into pieces. In-gel digestion was performed as
described by Ha et al. (21) modified as follows: 30 
 
 
 
l of 100 mM
ammonium bicarbonate, 1 mM CaCl
 
2
 
, pH 8.9, and 5 
 
 
 
l of
trypsin solution (200 
 
 
 
g/ml, Promega) were added to the gel
particles. After 10’, 30 
 
 
 
l of 60% acetonitrile in 100 mM ammo-
nium bicarbonate, 1 mM CaCl
 
2
 
 pH 8.9 (final concentration:
30%) were added to the mixture. After overnight incubation at
37
 
 
 
C, the supernatant was recovered and dried in a vacuum cen-
trifuge (Savant Instruments) until the volume was reduced to 30
 
 
 
l; 30 
 
 
 
l of 0.25% formic acid was then added. The sample was
filtered using a 0.02 
 
 
 
m Anodisc 13 filter (Whatman) in a Micro-
Filter system (ProteinSolutions).
 
LC/ESI-MS/MS Analysis of Tryptic Peptides.
 
An automated LCQ-
DECA MS/MS ion trap mass spectrometer coupled to a HPLC
Surveyor (Thermo Finnigan) and equipped with a Hypersil BDS,
C
 
18
 
 column, 1 
 
 
 
 100 mm (ThermoHypersil) were used. Peptides
were eluted from the column using an acetonitrile gradient, 5% B
for 3 min followed by 5 to 90% B within 52 min (eluent A:
0.25% formic acid in water; eluent B: 0.25% formic acid in aceto-
nitrile) at a flow-rate of 50 
 
 
 
l/min. The capillary of the ion trap
was kept at 200
 
 
 
C and the voltage at 30 V. Spray voltage was 5.0
kV. Spectra were acquired in automated MS/MS mode: each full
MS scan (in the range 400–2,000 
 
m/z
 
) was followed by three
MS/MS of the most abundant ions, using relative collision energy
of 35%. Computer analysis of peptide MS/MS spectra was per-
formed using the version 1.2 of the TurboSEQUEST software
(University of Washington, licensed to ThermoFinnigan Corp.)
and searched against the National Center for Biotechnology In-
formation (NCBI) human protein database.
 
CHO-K Cell Transfectants and Chimeric Molecules.
 
CHO-K cells
were stably transfected with either the pSV2-PVR
 
 
 
 (gift of Dr.
Akio Nomoto, University of Tokyo, Tokyo, Japan) or the
pLX2S.B1 (Nectin-2
 
 
 
) or the pLX2L.C12 (Nectin-2
 
 
 
) vectors
(20, 22)
Construction, production, and purification of soluble Nectin-
2-Fc, PVR-Fc, and Nectin-4tr-Fc (a truncated form of Nectin-4
ectodomain) were already described (20, 23). Briefly, Nectin
ectodomains were fused to the Fc portion of human IgG1 using
the pCOS Fc Link vector (Smith Kline Beecham). Proteins were
produced in COS cells with FuGENE6 according to the recom-
mendations of the manufacturer (Roche Diagnostics). The pro-
teins were purified from supernatants on Affi-Gel protein A. Pu-
rification was controlled by Coomassie Blue-stained SDS-PAGE.
 
RT-PCR Amplification of cDNA Encoding for DNAM-1 and
Transient Cell Transfection.
 
Total RNA extracted using peQGold
RNA pure (peQLab) from a polyclonal NK cell population was
reverse transcribed using oligodT priming. Primers used for
cDNA amplification of complete DNAM1-ORF (1124 bp) were
the following: 5
 
 
 
 AGA ACC AGC CTT TCA AAC AG
(DNAM-frw) and 5
 
 
 
 CTT GGG TAG TGG AAA AAA ATT G
(DNAM rev). Amplification was performed for 30 cycles (30 s at
94
 
 
 
C, 30 s at 55
 
 
 
C, 30 s at 72
 
 
 
C), followed by 7 min incubation
at 72
 
 
 
C, using AmpliTAQ (PerkinElmer/Applied Biosystems).
The cDNA obtained was subcloned in VR1012 expression vec-
tor (Vical Inc.) and sequenced.
COS7 cells were transiently transfected with VR1012/
DNAM-1 construct using Fugene 6 (Roche). Briefly, cells were
seeded at 5 
 
 
 
 10
 
5
 
/plate, 24 h later they were incubated with 6 
 
 
 
g
of plasmid and 10 
 
 
 
l of FuGENE6 in DMEM/10% FCS. After
48 or 72 h, transfected cells were used for cytofluorimetric analysis.
Cell transfectants were stained with GN18 or FS123 anti-DNAM-1
mAbs followed by PE-conjugated goat anti–mouse IgG second
reagent (Southern Biotechnology Associates, Inc.). In parallel,
DNAM-1 transfected cells were stained with PVR-Fc, Nectin-2-
Fc, or Nectin-4tr-Fc soluble chimeric molecules (from 0.2 to 1
 
 
 
g/sample) followed by PE-conjugated goat-anti-human IgG an-
tibody (Southern Biotechnology Associates, Inc.) and analyzed by
flow cytometry using a FACSort™ (Becton Dickinson).
 
Results
 
Isolation of mAbs against NK-susceptible Target Cells.
 
In an
attempt to identify novel cell surface ligands recognized by
orphan triggering NK receptors, mice were immunized
with the NK-susceptible M14 (human melanoma) or 293T
(human embryonic fibroblasts) cell lines (15). After cell fu-
sion, the mAbs obtained were screened for their capability
of inhibiting the NK cytotoxicity against the immunizing
cells. Both target cells did not express CD48 (i.e., the 2B4
ligand) while they did express the NKG2D ligands. In par-
ticular, M14 expressed ULBP2 while 293T expressed
MICA, ULBP2, and ULBP3 (not shown). Thus, in order
to select mAbs directed to ligands different from MICA
and ULBPs, the cytolytic assay was performed in the pres-
ence of an anti-NKG2D mAb to block NKG2D on the ef-
fector NK cells (15). These were represented either by
polyclonal NK cell populations or by the NK92 NK cell line
(surface phenotype: CD16
 
 
 
, NKp46
 
 
 
, NKp30
 
 
 
, NKp44
 
 
 
,
NKG2D
 
 
 
, 2B4
 
 
 
, NTB-A
 
 
 
, DNAM-1
 
 
 
) (8). Using this
experimental approach, four mAbs were selected that in-
hibited the cytotoxicity residual after NKG2D blocking
(Fig. 1). In particular, M5A10 and M2C24 mAbs were iso-
lated from M14 immunization, while L95 and L14 mAbs
were selected from 293T immunization. It is of note that
the inhibitory effect of the four selected mAbs was higher
when the NK92 cell line was used, instead of normal poly-
clonal NK cells, as a source of effector cells. This is likely to
reflect differences in the expression and/or surface density
of the various triggering NK receptors in the two different
effector cells. Indeed, normal polyclonal NK cells, unlike
the NK92 cell line, express NKp46, a major triggering NK
receptor that is also involved in recognition and killing of
both M14 and 293T cells (24). The inhibition mediated byT
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L14 mAb was lower as compared with the other mAbs par-
ticularly when the effector cells were represented by
NK92. This suggested that the molecule(s) recognized by
L14 mAb might be different from those recognized by the
other mAbs.
Altogether, the above data suggested that the selected
mAbs could recognize surface structures functioning as cel-
lular ligands for triggering receptors other than NKG2D.
Thus, we next evaluated, by indirect immunofluorescence
and cytofluorimetric analysis, the distribution of the surface
molecules reactive with the selected mAbs. As shown in
Table I, all mAbs brightly stained not only the immunizing
cells but also a large panel of tumor cell lines of different
histotype. Notably, the cellular distribution of the mAbs-
reactive molecule(s) was mostly overlapping although mi-
nor differences could be detected between the reactivity of
L14 and that of the other mAbs (see for example the
MOLT4 cell line in Table I). Finally, the analysis of normal
leukocytes revealed that all four mAbs did not react with
resting NK, B, and T cells or with in vitro activated NK
cells. Low reactivity could be detected in monocytes and
granulocytes (with all four mAbs), while in vitro–activated
T cells were weakly stained by L95, M5A10, and M2C24
mAbs but not by L14 mAb.
 
Biochemical Characterization of the Surface Molecules Recog-
nized by the Selected mAbs.
 
Different cell lines were sur-
face labeled with biotin and cell lysates were immunopre-
cipitated with one or another mAb. In all instances,
M5A10, M2C24, and L95 mAbs immunoprecipitated a
surface molecule of 
 
 
 
70 kD both under reducing (Fig. 2
A) and nonreducing conditions (not depicted). The protein
backbone remaining after treatment with N-glycosidase F,
Figure 1. Inhibition of NK-mediated cytotoxicity by M5A10,
M2C24, L95, and L14 mAbs. A polyclonal NK cell population (top pan-
els) or the NK92 NK cell line (bottom panels) pretreated with anti-
NKG2D mAb (BAT221; for 15 min at room temperature) were analyzed
for cytolytic activity against the indicated target cell lines in the presence
of either a control mAb (white bars) or one or another of the indicated
mAbs (black bars). The effector/target ratio used was 10:1 for polyclonal
NK cells and 20:1 for NK92. The results are representative of three inde-
pendent experiments; the standard deviation of the mean of the triplicates
was  5%.
 
Table I.
 
Surface Reactivity of the Selected mAbs on Different 
Cell Types
 
Cells Histotype
L95, M5A10,
M2C24 mAbs
L14
mAb
Resting NK cells
 
  
 
Activated NK cells
 
  
 
Resting T cells
 
  
 
PHA Blasts
 
 
 
/
 
  
 
Resting B cells
 
  
 
Monocytes
 
 
 
/
 
  
 
/
 
 
 
Granulocytes
 
 
 
/
 
  
 
/ 
YT NK cell line   
NK92 NK cell line   
CEM T leukemia   
MOLT4 T leukemia   
Jurkat T leukemia   
H9 T leukemia     / 
HSB2 T leukemia   
Raji Burkitt lymphoma   
DAUDI Burkitt lymphoma   
Namalwa Burkitt lymphoma    / 
LCL 721.221 EBV cell line   
LCL C1R EBV cell line   
RPMI 18226 EBV cell line    / 
K562 Erythroleukemia     
MM6 Promyelocytic leukemia     / 
U937 Myeloid leukemia    / 
293T Embryonic fibroblasts      
M14 Melanoma     
MEL15392 Melanoma     / 
FO-1 Melanoma     
Me 1386 Melanoma     
Me 18105 Melanoma      
A549 Lung carcinoma     
SMMC Hepatoma   
HELA Cervical carcinoma   
IGROV-1 Ovarian carcinoma   
SKNEP Kidney carcinoma   
A172 Glioblastoma     
HT29 Colon carcinoma     
SW480 Colon carcinoma      
SK-N-BE Neuroblastoma  /   / 
LAN5 Neuroblastoma     
HTLA260 Neuroblastoma    / 
YAC-1 Murine thymoma   
BW1502 Murine thymoma   
P815 Murine mastocytoma   
COS-7 Monkey kidney fibroblast   
CHO-K Chinese hamster, ovarian 
carcinoma
  
Normal cells and tumor cell lines of different histotype were analyzed by indirect
immunofluorescence and FACS® analysis for reactivity with the indicated mAbs.
Cells are of human origin unless otherwise specified. Mean fluorescence intensity
(MFS): overlapping the negative control ( )(MFI set on 5); MFI below 20 ( / );
MFI between 20 and 100 ( ); MFI over 100 (  ). Immunizing cells (M14 and
293T) and MOLT4 are in bold.T
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displayed a molecular mass of  40–45 kD. L14 mAb im-
munoprecipitated two surface molecules of  65 and 60
kD, respectively, both under-reducing (Fig. 2 B) and non-
reducing conditions (not shown). After treatment with
N-glycosidase F these molecules displayed protein back-
bones of  60 and 55 kD, respectively. These results, to-
gether with data on cell surface distribution and cytotoxic-
ity suggested that L14 mAb may recognize surface
molecule(s) distinct from that reactive with the other
mAbs. To gain further information, 293T cells were im-
munoprecipitated with each of the selected mAbs and, after
blotting, probed either with the same mAb used for immu-
noprecipitation or with a different mAb. M5A10 (Fig. 3,
left panel) and M2C24 (not shown) reacted with the mole-
cule immunoprecipitated by L95 mAb thus confirming that
they recognized the same molecule. On the other hand,
they did not recognize the molecule immunoprecipitated
by L14 mAb and vice versa. It is of note that both the 65
and 60 kD surface molecules were recognized by L14 mAb
also by Western blot (Fig. 3, right panel), suggesting that
they might represent alternative forms of a single molecule.
Purification and Sequence Analysis of the Molecules Recog-
nized by the Selected mAbs To ascertain the identity of the
surface molecules identified by the four selected mAbs, cell
membranes were prepared from 293T cells. After lysis,
molecules were purified by affinity chromatography using
L95 or L14 mAbs covalently bound to sepharose beads.
Eluted proteins were concentrated and analyzed in SDS-
PAGE under nonreducing conditions. The quality of the
purification process was verified by the Western blot analy-
sis of the eluted molecules with the corresponding mAb
(not shown). After running, polyacrylamide gels were
stained with coomassie blue. The band corresponding to
the L14-specific molecules(s) were excised from the gel for
the in-gel tryptic digestion and analyzed on a LC-MS/MS
system. Fig. 4 A shows the ion chromatogram displaying
the base peaks of the tryptic digest of the L14-specific mol-
ecule(s). Analysis of the mass spectra (full MS and MS/MS)
using the TurboSEQUEST software showed five peptides
with m/z (mass-to-charge ratio) of 1455.9, 921.5, 857.6,
961.5, and 1635.6. Fig. 4 B shows a representative frag-
mentation spectrum of peptide 961.5 m/z, from which its
sequence (AEQVIFVR) was deduced. Similar spectra were
obtained for the other four peptides of the same protein
(see Table II). These results identified the L14-reactive
protein(s) as Nectin-2 (  and   isoforms; CD112). It is of
note that the Nectin-2   and   isoforms are characterized
by identical extracellular portions but different transmem-
brane and cytoplasmic regions (long and short, respec-
tively). This was in agreement with our biochemical data
showing that L14 mAb specifically recognized two surface
molecules of different molecular mass (see above).
Similar experiments were performed for the molecule
recognized by the M5A10, M2C24, and L95 mAbs. In this
case, the search in the NCBI human protein database of the
MS/MS spectra analysis matched with the Poliovirus Re-
ceptor   and   isoforms (PVR, CD155; for detected ions
and amino acid sequences see Table II). The predicted mo-
lecular masses of identified proteins (57743 and 51358 kD
for Nectin-2  and  , respectively, and 42912 and 45351
Figure 2. Biochemical characterization of the surface molecules recog-
nized by M5A10, M2C24, L95, and L14 mAbs. The indicated cell lines
were surface labeled with biotin and immunoprecipitated with L95,
M5A10, M2C24 (top panel), and L14 (bottom panel) mAbs. Samples
were treated ( ) or not ( ) with N-glycosidase F and analyzed in an 8%
SDS-PAGE under reducing conditions. Molecular weight markers (kD)
are indicated.
Figure 3. Western blot analysis of M5A10, L95, and L14 mAbs. The
indicated cell lines were immunoprecipitated with L95 and L14 mAbs.
Samples were analyzed in an 8% SDS-PAGE under nonreducing condi-
tions and probed with biotin-labeled M5A10 and L14 mAbs. Molecular
weight markers (kD) are indicated. DAUDI cell lines were used as nega-
tive control.T
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kD for PVR   and  , respectively) were in agreement with
those obtained from SDS electrophoresis (see Fig. 2).
To unequivocally confirm that the two molecules corre-
sponded to PVR (CD155) and Nectin-2 (CD112), respec-
tively, hamster CHO-K cells either untransfected or trans-
fected with PVR or Nectin-2 constructs were analyzed for
their surface reactivity with the four mAbs. In all instances,
no reactivity could be detected in untransfected CHO-K
cells (not shown). On the other hand, M5A10, M2C24,
and L95 mAbs specifically recognized PVR  cell transfec-
tants while Nectin-2  and Nectin-2  transfectants were
uniquely stained by L14 mAb (Fig. 5).
Identification of DNAM-1 as the Surface NK Receptor Spe-
cific for PVR and Nectin-2. To identify the receptor(s) ex-
pressed by NK cells that specifically recognize PVR or
Nectin-2 on target cells, chimeric molecules formed by the
extracellular domain of PVR or Nectin-2 molecules and
by the Fc portion of human IgG1 were analyzed for their
surface reactivity with COS-7 cells transiently transfected
with a panel of activating NK receptors. PVR-Fc and
Nectin-2-Fc did not react with untransfected cells or with
COS-7 cells transfected with NKp46 and NKp30 (not
shown). On the contrary, COS-7 cells transfected with
DNAM-1 (CD226) were brightly stained by both PVR-
Fc and Nectin-2-Fc molecules (Fig. 6). Nectin-4tr-Fc
molecule, used as control, did not display surface reactivity
with either untransfected or transfected COS-7 cells. In
conclusion, all these data demonstrate that PVR and Nec-
tin-2 represent specific cell surface ligands recognized by
DNAM-1 receptor.
The Interaction between DNAM-1 and PVR or Nectin-2
Promotes Human NK Cell Triggering and Cytotoxicity. In the
first set of experiments NK cells were assessed for cytolytic
activity against the CHO-K hamster cell line either un-
transfected or transfected with PVR or Nectin-2 con-
structs. As shown in Fig. 7 A, NK92 cells killed untrans-
Figure 4. Extract ion chromato-
gram of the L14-antigen tryptic digest
and representative fragmentation spec-
trum for ion m/z 961. (A) Ion chro-
matogram displaying the base peaks of
the tryptic digest of L14-specific mol-
ecule analyzed on a LC-MS/MS sys-
tem as described in Materials and
Methods. (B) MS/MS of the peptide
with molecular ion 961.55 m/z from
which the amino acid sequence
AEQVIFVR was obtained in the au-
tomated system from NH2 to COOH
terminal and vice versa.T
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fected CHO-K cells. Cytotoxicity was mostly dependent
on NKp30–mediated recognition of undefined xenogeneic
ligand(s) expressed on hamster cells since it was sharply in-
hibited by mAb-mediated masking of NKp30. On the
contrary, in agreement with the lack of human PVR or
Nectin-2 ligands on the CHO-K cells, mAb-mediated
masking of DNAM-1 had no inhibitory effect. On the
other hand, the NK92-mediated lysis of CHO-K cells that
had been transfected with either PVR or Nectin-2 con-
structs was only partially inhibited by anti-NKp30 mAb. In
these cell transfectants, cytotoxicity was partially inhibited
also by anti-DNAM-1 mAb. Remarkably, the simulta-
neous masking of NKp30 and DNAM-1 virtually abro-
gated cytotoxicity (Fig. 7 A). These results were further
substantiated by experiments in which the effector NK cells
were represented by the YT NK cell line. YT express
DNAM-1 and 2B4 but lack CD16, NKp30, NKp46,
NKp44, and NKG2D molecules. Thus, due to the lack of
the major triggering NK receptors, it is conceivable that in
these cells DNAM-1 may play a predominant role in in-
ducing cytotoxicity. As shown in Fig. 7 A, YT cells did not
kill untransfected CHO-K cells. However, they lysed both
PVR and Nectin-2 CHO-K cell transfectants. Moreover,
mAb-mediated masking of either DNAM-1 or PVR or
Nectin-2 virtually abrogated target cell lysis.
In most experiments, the YT-mediated lysis of PVR
transfectants was slightly higher than that of Nectin-2
transfectants. As, in CHO-K transfectants the expression of
Nectin-2 was similar or even higher than that of PVR the
above difference may reflect an intrinsic disparity between
the two ligands in the ability to promote DNAM-1–depen-
dent NK cell activation.
DNAM-1 Contributes to NK-mediated Lysis of Tumor
Cells. As our data demonstrated that DNAM-1 recog-
nizes two different ligands on target cells we next analyzed
the role of the interactions between DNAM-1 and PVR
and Nectin-2 in the NK-mediated cytotoxicity against a
panel of tumor target cells. In a first set of experiments ef-
fector cells were represented by the NK92 NK cell line. As
target cells expressed one or another NKG2D ligands, ex-
periments were performed in the presence of anti-NKG2D
mAb (see above). Although not shown, we could not de-
tect any DNAM-1 involvement in NK-mediated lysis of
target cells that lack PVR and/or Nectin-2. Lysis of PVR ,
Nectin-2  targets (see the representative HELA, Me1386,
and FO-1 in Fig. 7 B) was partially inhibited by mAb-medi-
ated masking of PVR or Nectin-2. Again, PVR appeared
to play a predominant role in inducing DNAM-1–depen-
dent NK cell triggering as compared with Nectin-2. Im-
portantly however, the combined masking of both PVR
and Nectin-2 resulted in inhibition of lysis comparable to
that obtained by mAb-mediated masking of DNAM-1. Al-
Table II. Amino Acid Sequence and m/z of Peptides Obtained by 
Tryptic Digestion of L14- or L95 mAb-defined Antigens
Identified peptides m/z
Nectin-2  a and  b MGPSFPSPKPGSER 1,455.9
VQVLPEVR 921.5
FTLVPSGR 857.6
AEQVIFVR 961.5
Nectin-2  b SPGGAGGGASGDGGFYDPK 1,635.6
PVR  c and  d VLAKPQNTAEVQK 1,425.8
QAELTVQVK 1,015.6
VQLTGEPVPPMAR 1,297.7
HGESGSMAVFHQTQGPSYSESK 2,351.0
RLEFVAAR 961.6
Peptides identified from L14 specific protein, corresponding to Nectin-
2  (long) or   (short) isoforms, and from L95 specific protein,
corresponding to PVR  and   are shown. The bands, from SDS-PAGE,
corresponding to the L14 or L95-specific molecules, were trypsin
digested and analyzed on a LC-MS/MS system as described in Materials
and Methods. The m/z (mass-to-charge ratio) of each peptide is reported. 
a(NCBI, gi 12643789, Nectin-2 ). 
b(NCBI, gi 2118920, Nectin-2 ).
c(NCBI, gi 319893, PVR ).
d(NCBI, gi 319892, PVR ). 
Figure 5. Surface reactivity of M5A10, M2C24, L95 and L14 mAbs with CHO-K cells transfected with the PVR or Nectin-2 constructs CHO-K cells
transfected with the PVR  or Nectin-2  (or Nectin-2 , data not shown) constructs were stained with the indicated mAbs followed by PE-conjugated
goat anti–mouse isotype-specific second reagent and analyzed by flow cytometry. White profiles indicate cells incubated with the second reagent only.T
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together, these data suggest that PVR and Nectin-2 coop-
erate in the induction of DNAM-1–dependent killing of
target cells. In addition, they suggest that they represent the
major cellular ligands of DNAM-1.
In another set of experiments we evaluated the role of
DNAM-1-mediated recognition of PVR and Nectin-2 us-
ing polyclonal NK populations as a source of effector cells.
These experiments were performed in order to compare
the relative contribution of DNAM-1 versus NCR in the
process of NK-mediated killing of different tumors includ-
ing carcinomas, melanomas, and neuroblastomas.
It is of note that, at variance with NK92 or YT cells, the
cytolytic activity of polyclonal NK cells is induced via
multiple triggering receptors. These may display a more or
less predominant involvement depending upon the ex-
pression of their cellular ligands at the target cell surface.
Fig. 7 C shows the results of cytotoxicity experiments in
which polyclonal NK cells were analyzed against three
representative tumor cell lines. Lysis of HELA carcinoma
was substantially inhibited by the use of anti-NCR mAbs
although some inhibition was also evident in the presence
of anti-DNAM-1 mAb; only the combined use of both
reagents could abrogate lysis. In the case of FO1 mela-
noma, again a predominant role of NCR could be de-
tected although blocking of DNAM-1 also resulted in po-
tent inhibition. This was confirmed also by the finding
that blocking both NCR and DNAM-1 (or its ligands)
could virtually abrogate cytotoxicity. Finally, in the case of
HTLA260 neuroblastoma, blocking of DNAM-1 resulted
in an inhibitory effect comparable to that induced by anti-
NCR mAbs. Although not shown, blocking of PVR
alone on HTLA260 resulted in inhibition comparable to
that mediated by anti-DNAM-1 mAb. This data is consis-
tent with the finding that HTLA260 express PVR but
very little Nectin-2.
In conclusion, these experiments further indicate that kill-
ing of different tumor targets by normal NK cells is the re-
sult of the engagement of multiple triggering receptors. The
involvement of DNAM-1 can be appreciated in mAb-depen-
dent blocking experiments against various tumors of differ-
ent histotype. However we could not identify target cells
that were lysed in a strictly DNAM-1–dependent manner.
The most prominent inhibition with anti-DNAM-1 an-
tibodies was detected against the neuroblastoma cell line al-
though this may simply reflect a reduced surface density of
the NCR ligands on this target.
Discussion
In this study, mAbs specific for molecules expressed at
the cell surface of NK-susceptible target cells were selected
on the basis of their ability to down-regulate the NK-medi-
ated cytolytic activity. As revealed by the LC-MS/MS amino
acid sequence analysis, the surface molecules recognized by
the selected mAbs were PVR and Nectin-2, i.e., two mem-
bers of the Nectin family (23). Analysis of the surface reac-
tivity of PVR-Fc and Nectin-2-Fc soluble hybrid molecules
indicated that both molecules represent specific ligands of
the DNAM-1 activating receptor (10, 11). The functional
interaction between DNAM-1 and PVR or Nectin-2 was
substantiated by cytolytic assays in which NK cells were
used as effectors and hamster CHO-K cells transfected with
PVR or Nectin-2 as target cells. Indeed, in these experi-
ments mAb-mediated masking of DNAM-1 or PVR or
Nectin-2 resulted in inhibition or even in virtual abroga-
tion of cytotoxicity.
PVR (18) and Nectin-2 (19, 20) are closely related mol-
ecules encoded by genes located in the 19q13 chromo-
somal region. Alternative splicing of PVR (PVR  and
PVR ) and Nectin-2 (Nectin-2  and Nectin-2 ) yield to
surface molecules characterized by identical extracellular
portions, formed by three Ig-like domains in the order
V/C/C (18, 19). Alternative splicing sites of PVR and
Nectin-2 isoforms are located in the cytoplasmic and in the
extracellular regions respectively. Differences in length of
the Nectin-2  and   cytoplasmic tails result in a short or
long isoform, respectively. Importantly, PVR and Nectin-2,
are highly expressed in tumor cell lines of epithelial or neu-
ronal origin such as carcinomas, melanomas and neuroblas-
tomas (see Table I).
DNAM-1 is a transmembrane glycoprotein, involved in
lymphocyte adhesion and signaling, characterized by two
extracellular Ig-like domains and by a cytoplasmic portion
containing three tyrosine residues (11). It is expressed by
virtually all human NK cells, T cells, monocytes, and by a
small subset of B lymphocytes. Upon mAb-mediated cross-
linking DNAM-1 transduces activating signals resulting in
Figure 6. Surface reactivity of PVR-Fc or Nectin-2-Fc molecules with DNAM-1 cell transfectants COS-7 cells transfected with DNAM-1 construct
were stained with PVR-Fc, Nectin-2-Fc, or Nectin-4tr-Fc (negative control) molecules, followed by PE-conjugated goat anti–human second reagent,
or with GN18 (anti-DNAM-1) mAb, followed by PE-conjugated goat anti–mouse isotype-specific second reagent. Samples were analyzed by flow cy-
tometry. White profiles indicate cells incubated with the second reagent only.T
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tyrosine phosphorylation of DNAM-1 itself, enhancement
of cytotoxicity and cytokine production in both T and NK
cells. Interestingly, the role played by DNAM-1 in both
CTL- and NK-mediated killing varied upon the target cells
analyzed. Thus, mAb-mediated blocking of DNAM-1 re-
sulted in inhibition of cytotoxicity against colon or ovarian
carcinomas, K562, Jurkat, and U937 cell lines. In contrast,
lysis of the Epstein-Barr virus (EBV)-transformed LCL
721.221 B cell lines was unaffected (11). These data sug-
gested that cell surface antigen(s) that are broadly expressed
in both nonhematopoietic and hematopoietic tissues could
represent the DNAM-1 ligand(s). Our present identifica-
tion of PVR and Nectin-2 as DNAM-1–specific cellular
ligands, is in agreement with this concept. Indeed, carcino-
mas and hematopoietic cell lines such as K562, Jurkat, and
U937 express PVR and Nectin-2. Moreover, in accor-
dance with the inability of anti-DNAM-1 mAb to inhibit
T- or NK-mediated lysis of B-EBV cells, the majority of
B-EBV cell lines analyzed did not express both molecules
(see Table I). The involvement of DNAM-1 in the NK-
mediated lysis of various tumor cell lines analyzed consis-
tently correlated with the expression of PVR and Nectin-2
on target cells suggesting that they may represent major
ligands for DNAM-1. It is of note that the involvement of
Figure 7. mAb-mediated disruption of DNAM-1/ligands interaction inhibits the NK-mediated lysis of PVR or Nectin-2 cell transfectants and of tu-
mor cell targets. (A) NK92 or YT NK cell lines were analyzed for cytolytic activity against the CHO-K cells either untransfected or transfected with
PVR  or Nectin-2  constructs. Cytolytic assays were performed either in the absence of mAb (white bars) or in the presence of F252, GN18, L14, and
L95 mAbs to the indicated molecules (black bars). The effector/target ratio used was10:1 for NK92 and 40:1 for YT. Similar results were obtained with
Nectin-2  transfectants (data not shown). (B) NK92 NK cell line pretreated with anti-NKG2D mAb (for 15 min at room temperature) was analyzed for
cytolytic activity against the indicated tumor target cells in the presence of either a control mAb (white bars) or mAbs (as in panel A) to the indicated
molecules (black bars). The effector/target ratio used was 10:1. (C) A polyclonal NK cell population pretreated with anti-NKG2D mAb was analyzed for
cytolytic activity against the indicated tumor target cells in the presence of either a control mAb (white bars) or mAbs to NCR (F252 and KL247),
DNAM-1 (KRA236), or DNAM-1-Ligands (L95 and L14). These mAbs were used alone or in combination as indicated. The effector/target ratio used
was 4:1. The results are representative of four independent experiments; the standard deviation of the mean of the triplicates was  4%.T
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DNAM-1 in NK cytotoxicity could be better appreciated
when NK92 or YT were used as effectors instead of nor-
mal NK cells. This data is explained by the fact that normal
NK cells express several activating receptors and corecep-
tors that cooperate in target cell recognition and killing (5).
As a consequence, mAb-mediated blocking of individual
receptors may not significantly inhibit cytotoxicity since
most target cells express multiple ligands for the various re-
ceptors and coreceptors. On the contrary, the NK cell lines
NK92 and YT lack one or more major activating receptor
involved in NK cell cytotoxicity (8). Thus, the mAb-medi-
ated disruption of a single receptor/ligand interaction
(namely DNAM-1/PVR or Nectin-2) was sufficient to
significantly inhibit cytolytic activity.
Our data shows that DNAM-1, upon engagement by
the specific ligands (i.e., PVR and Nectin-2), cooperates
with other triggering NK receptors in the induction of NK-
mediated cytotoxicity. In this context, the analysis of poly-
clonal NK populations that express the whole set of
triggering NK receptors indicated that the induction of cy-
totoxicity against the carcinoma, melanoma, and neuroblas-
toma cell lines analyzed is consequent to the engagement of
both NCR and DNAM-1 (Fig. 7 C). Most tumor target
cells overexpressing DNAM-1 ligands displayed a reduced
expression of HLA class I molecules. Thus, in the absence
of effective HLA class I/inhibitory receptors interactions,
the engagement of DNAM-1 and other triggering NK re-
ceptors, resulted in induction of cytolytic activity. In the
case of normal target cells, however, DNAM-1/ligands in-
teractions should not result in activation of NK-mediated
killing. Although some normal cells may express the
DNAM-1 ligands they also express normal levels of HLA
class I molecules that block the NK cell function upon in-
teraction with inhibitory NK receptors. In this context, it is
of note that normal endothelial or epithelial cells express
members of the Nectin family that appear to be localized to
intercellular borders (20). This specific localization may
have relevant implication in the process of leukocyte recir-
culation. Leukocyte recirculation from the blood to lym-
phoid organs is critical for the induction of inflammatory
responses. To recirculate, leukocytes must pass between
endothelial cells, a process called extravasation. While
LFA-1 molecules are crucial for the firm adhesion of leu-
kocytes to endothelium (25), the final step, i.e., leukocyte
migration between endothelial cells is largely unknown.
Given the particular endothelial localization of nectins and
the fact that DNAM-1 is expressed by different leukocytes,
it is conceivable that Nectin/DNAM-1 interactions may
also play a role in the interaction between leukocytes and
endothelial cells in the process of leukocyte recirculation.
It is of note that DNAM-1 and LFA-1 molecules are
physically and functionally associated in normal cells (12).
Accordingly, in the absence of LFA-1, as in the case of
LAD1 patients, the function of DNAM-1 was defective.
Importantly, in normal NK cells not only the mAb-medi-
ated cross-linking of DNAM-1 itself but also that of LFA-1
induces tyrosine phosphorylation of DNAM-1. These data
support the notion that LFA-1/CAMs interactions may
precede and modulate DNAM-1/Nectins interactions in
target cell recognition and, possibly, in the process of ex-
travasation.
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